Research Analysts Offer Predictions for Apellis Pharmaceuticals, Inc.'s Q2 2025 Earnings (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) – Investment analysts at Zacks Research raised their Q2 2025 earnings estimates for Apellis Pharmaceuticals in a note issued to investors on Thursday, July 13th. Zacks Research analyst A. Chakraborty now forecasts that the company will post earnings of $0.41 per share for the quarter, up from their […]

Related Keywords

,Adamj Townsend ,Cedric Francois ,News Ratings For Apellis Pharmaceuticals Daily ,Apellis Pharmaceuticals Inc ,Citigroup ,Neuberger Berman Group ,Apellis Pharmaceuticals Company Profile ,Nasdaq ,Goldman Sachs Group ,Zacks Research ,Apellis Pharmaceuticals Price Performance ,Securities Exchange Commission ,Cim Investment Management Inc ,Advisor Group Holdings Inc ,Apellis Pharmaceuticals ,Free Report ,Apellis Pharmaceutical ,Get Free Report ,Exchange Commission ,Investment Management ,Group Holdings ,Berman Group ,Handelsbanken Fonder ,Apellis Pharmaceuticals Daily ,